PolyNovo Limited (ASX:PNV)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
Development, Manufacturing and Commercialisation of the NovoSorb Technology	128.70M	103.23M	65.67M	41.89M	29.34M
Development, Manufacturing and Commercialisation of the NovoSorb Technology Growth	24.67%	57.20%	56.76%	42.78%	32.19%
Total	128.70M	103.23M	65.67M	41.89M	29.34M
Total Growth	24.67%	57.20%	56.76%	42.78%	32.19%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017	Jun 30, 2016
United States of America	96.99M	79.84M	51.76M	35.86M	24.32M
United States of America Growth	21.48%	54.23%	44.36%	47.42%	30.31%
Australia and New Zealand	7.95M	6.56M	4.77M	3.21M	3.24M
Australia and New Zealand Growth	21.19%	37.56%	48.72%	-1.15%	14.95%
Other Countries	22.31M	16.80M	8.71M	2.38M	1.59M
Other Countries Growth	32.82%	92.86%	266.56%	49.38%	137.96%
Total	127.24M	103.19M	65.24M	41.44M	29.16M
Total Growth	23.31%	58.17%	57.44%	42.12%	31.60%

Source: S&P Global Market Intelligence.